Skip to main content
Premium Trial:

Request an Annual Quote

Xifin, Translational to Combine Software Products

NEW YORK (GenomeWeb) – Xifin, a healthcare cloud computing company, has signed an agreement with Translational Software to integrate Translational's pharmacogenetics knowledgebase and interpretation platform with Xifin LIS Anywhere, its laboratory information system.

According to the partners, combining their products will provide molecular diagnostics laboratories with a complete, seamless solution that supports their efforts to determine the most effective treatments for patients based on treatment guidelines, recommendations, regulatory filings, and more.

The combined system will include features for ordering tests, interpreting results, and managing laboratory workflow, as well as offer capabilities for billing, and financial management, the partners said. Users will also have access to features for generating reports containing information on the genetic factors that affect the efficacy and toxicity of drugs as well as risk factors relevant to patient's health in order to guide clinical decision making.

"Xifin's in-depth experience and understanding of the needs of high-growth molecular diagnostic companies make them an ideal partner as we continue to expand our knowledge solutions to make genetic testing an efficient and cost-effective tool for clinicians," Don Rule, Translational Software's founder and CEO, said in a statement. "We are pleased to be part of an integrated solution that helps leading labs link a patient’s genetic make-up to specific clinical guidance."

"Our partnership with Translational Software will be instrumental in helping Xifin fulfill its mission to improve the accuracy of laboratory test selection and result interpretation and support the information exchange needed for value-based healthcare initiatives," Lâle White, Xifin's CEO added. Translational Software's solutions "will accelerate our customer's ability to bring new genetic tests to market quickly, pursue the most effective patient therapies, and improve operating efficiency."

Financial and other terms of the agreement were not disclosed.